Actively Recruiting
Randomized Study of Intra-Articular Allocetra Versus Placebo for Treatment of Primary Knee Osteoarthritis
Led by Enlivex Therapeutics Ltd. · Updated on 2026-10-13
182
Participants Needed
17
Research Sites
60 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of intra-articular injections of Allocetra in people aged 64 and older who have moderate-to-severe primary knee osteoarthritis, a condition where joint cartilage breaks down and causes chronic knee inflammation, pain, and functional issues. This randomized, double-blind, placebo-controlled Phase IIb study compares Allocetra to a placebo to assess its potential benefits. Participants will receive three ultrasound-guided injections directly into the affected knee on Days 0, 14, and 28. Allocetra is a cell-based therapy made from modified allogeneic peripheral blood mononuclear cells designed to influence immune cells in the knee joint. The study includes two groups one receiving Allocetra injections and the other receiving placebo injections. After treatment, participants will be followed for 12 months to monitor outcomes. Throughout the study, participants will undergo assessments including pain and function evaluations using the Western Ontario and McMaster Universities Arthritis Index WOMAC at 3 and 6 months, safety monitoring for six months, and quality of life measurements. Researchers will track daily pain scores and other functional scales to evaluate the treatments impact. The studys total duration from treatment to follow-up is about one year.
CONDITIONS
Brief Title
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Research Team
L
Lior Binder
L
Lital Weinfeld Bergman
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here